Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Codetta
AddedFeb 15, 2024
UpdatedJun 18, 2026
Codetta

Codetta

Seed

Codetta Bio offers a multi-omic analysis platform for accelerated R&D of next-gen therapies, enhancing patient care.

HQ
Durham, NC, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Codetta Bio, founded with the mission to revolutionize life sciences research, focuses on providing a novel multi-omic analysis platform. Utilizing digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR), Codetta's integrated platform combines reagents, hardware, and software to enable multiplexed, multi-omic liquid biopsy and isolated DNA, RNA, and protein analyses. The company aims to accelerate research and development of next-generation therapies, ultimately enhancing patient care through precision medicine.

Notable figures affiliated with Codetta Bio include experts in biotechnology and life sciences who have contributed to the development of the platform. The company has attracted significant interest from investors focused on advancing medical research technologies. Key achievements include the successful integration of dsPCR and dsIPCR into a single workflow, which has garnered attention for its potential to elevate clinical trials with precise biomarker insights. Codetta Bio's impact lies in its ability to provide comprehensive, accurate biomarker measurements, thereby driving forward the capabilities of precision medicine.

Codetta - Similar Companies

Encodia logo

Encodia

encodia.com

BioDatomics logo

BioDatomics

biodatomics.com

OmicsChart logo

OmicsChart

omicschart.com

CasTag Biosciences logo

CasTag Biosciences

ChromaCode logo

ChromaCode

chromacode.com

Omix.ai logo

Omix.ai

Crispr QC logo

Crispr QC

crisprqc.com

Via Scientific logo

Via Scientific

viascientific.com

Bioinformatics logo

Bioinformatics

bioinfoinc.com

OmicsCraft logo

OmicsCraft

omicscraft.com

Mission Bio logo

Mission Bio

bioSyntagma logo

bioSyntagma

biosyntagma.com

Cornerstone Genomics logo

Cornerstone Genomics

Cellanome logo

Cellanome

cellanome.com

Protein Dynamic Solutions logo

Protein Dynamic Solutions

pdsbio.com

Codetta - Quick Facts

Who are Codetta's competitors?

Companies similar to Codetta include Encodia, BioDatomics, OmicsChart and CasTag Biosciences.

When was Codetta founded?

Codetta was founded in 2021.

Where is Codetta's headquarters located?

Codetta's headquarters is located in Durham, NC, US.

When was Codetta's last funding round?

Codetta's most recent funding round was for $2M (USD) in November 2022.

How much has Codetta raised to-date?

As of Nov 8, 2022, Codetta has raised a total of $17M (USD).

How many employees does Codetta have?

Codetta has 35 employees as of Feb 4, 2024.

Codetta - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Analytics
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Main Product
  • Biotechnology
  • Platform
Tags
  • Platform
  • Software
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software